•		Inclusion items Exclusion items								
Year Pharmaceutical &	Nutraceutical	Clear definition: symptom location	Clear definition: structural diagnosis	Clear definition: clinical diagnosis	History of trauma	History of dislocation	Evidence of subluxation or malalignment	History of surgery	Other reason for knee symptoms	
Hart 2019 [44]	PFP/CP (USA)	0	0	1	0	1	1	1	1	
Nakhostin-Roohi 2016 [60]	women athletes with AKP (Iran)	0	0	0	0	0	0	0	1	
Örsçelik 2015 [47]	Military with unilateral PFP (Turkey)	1	0	0	0	1	1	0	1	
Singer 2011 [57]	AKP (Australia)	1	0	1	0	1	0	1	1	
Marti-Bonmati 2009 [56]	degenerative patellar conditions (chondromalacia or OA) not requiring surgery (Spain)	0	1	0	1	1	0	0	1	
Kannus 1992 & 1999 [58,59]	patients with PFP (Finland)	1 As above	0	1	0	0	0	0	1	
Suter 1998 [49]	AKP, Sports Medicine clinic database (Canada)	1	0	0	1	1	0	1	1	
Raatikainen 1990 [48]	CP patients who attended a Sports Medicine Clinic (Finland)	1	1	1	0	0	0	0	1	
Fulkerson 1986 [55]	AKP (USA)	1	0	0	0	0	0	0	0	
Antich 1986 [45]	Physical therapy patients with knee	0	0	0	0	0	0	0	0	

Supplementary Table 1. Individual study population and quality assessment of eligibility criteria (1 indicates quality indicator present, 0 not present).

	extensor mechanism disorders (USA)								
Bentley 1981 [54]	CP patients (England)	1	1	1	0	0	1	0	0
Matoso 1980 [46]	CP patients in hospital rheumatology department who had opted for medication instead of surgery (Switzerland)	0	1	1	0	0	0	0	0
Darracott 1973 [53]	PFP in military members attending Army Medical Rehabilitation Unit (England)	1	0	1	0	0	0	0	0
Surgical									
Joseph 2020 [43]	isolated PFOA (UK)	0	0	1	0	0	0	1	1
		0 0	0 1	1	0	0 0	0	1 0	1
2020 [43] Odgaard	(UK) isolated PFOA								
2020 [43] Odgaard 2018 [40] Pagenstert	(UK) isolated PFOA (Denmark) patients with lateral patellar hypercompression syndrome	0	1	0	0	0	1	0	1

	cartilage lesions (USA)								
O'Neill 1997 [61]	athletic patients with AKP and lateral patellar tilting (USA)	1	0	1	0	1	1 sub/0 mal	0	1
Hejgaard 1982 [52]	patients admitted to hospital surgical department for CP (Denmark)	1	1	1	0	0	1	0	1

AKP = anterior knee pain; PFP = patellofemoral pain; OA = osteoarthritis; CP = chondromalacia patella; PFOA = patellofemoral osteoarthritis; sub = subluxation; mal = malalignment.

Intervention	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	GRADE certainty
Pharmaceutical & Nu	traceutical						
Oral							
NSAIDS	4 RCTs	One moderate RoB [54]	No	No	CI contains meaningful	Not tested (n<10)	Low
		Three high RoB	0	0	ES, n<400	0	
		[49,55,56]			-1		
		-1					
Chloroquine	1 RCT	High RoB [46]	One study	Pain outcome	CI not reported,	Not tested (n<10)	Very low
		-1	-1	unknown	n<400	0	
				validity/reliability	-1		
				-1			
Glucosamine	1 RCT	High RoB [56]	One study	No	CI exceeds meaningful	Not tested (n<10)	Very low
		-1	-1	0	ES, n<400	0	
					-1		
Pharmaceutical & Nu	traceutical						
Injections							
Glycosaminoglycan	2 RCTs	Two High RoB [48,58,59]	Yes	No	CI contains meaningful	Not tested (n<10)	Very low
,	2 RCTs	Two High RoB [48,58,59] -1	Yes -1	No 0	CI contains meaningful ES, n<400	Not tested (n<10)	Very low
Glycosaminoglycan	2 RCTs	0			5	Not tested (n<10)	Very low
Glycosaminoglycan	2 RCTs 1 RCT	0			ES, n<400	Not tested (n<10) Not tested (n<10)	Very low Low
Glycosaminoglycan Polysulphate		-1	-1	0	ES, n<400 -1		2
Glycosaminoglycan Polysulphate		-1 Low RoB [44]	-1 One study	0 No	ES, n<400 -1 CI contains meaningful		2
Glycosaminoglycan Polysulphate		-1 Low RoB [44]	-1 One study	0 No	ES, n<400 -1 CI contains meaningful ES; <400 participants		Low
Glycosaminoglycan Polysulphate Hyaluronic acid	1 RCT	-1 Low RoB [44] 0	-1 One study -1	0 No 0	ES, n<400 -1 CI contains meaningful ES; <400 participants -1	Not tested (n<10)	Low
Glycosaminoglycan Polysulphate Hyaluronic acid	1 RCT	-1 Low RoB [44] 0 High RoB [47]	-1 One study -1 One study	0 No 0 Military; Dose is	ES, n<400 -1 CI contains meaningful ES; <400 participants -1 CI spans meaningful	Not tested (n<10) Not tested (n<10)	Low
Glycosaminoglycan Polysulphate Hyaluronic acid	1 RCT	-1 Low RoB [44] 0 High RoB [47]	-1 One study -1 One study	0 No 0 Military; Dose is comparator	ES, n<400 -1 CI contains meaningful ES; <400 participants -1 CI spans meaningful ES, n<400	Not tested (n<10) Not tested (n<10)	Low
Glycosaminoglycan Polysulphate Hyaluronic acid Platelet-rich plasma	1 RCT 1 RCT	-1 Low RoB [44] 0 High RoB [47] -1	-1 One study -1 One study -1	0 No 0 Military; Dose is comparator -1	ES, n<400 -1 CI contains meaningful ES; <400 participants -1 CI spans meaningful ES, n<400 -1	Not tested (n<10) Not tested (n<10) 0	Low Very low
Glycosaminoglycan Polysulphate Hyaluronic acid Platelet-rich plasma	1 RCT 1 RCT	-1 Low RoB [44] 0 High RoB [47] -1 Moderate RoB [57]	-1 One study -1 One study -1 One study	0 No 0 Military; Dose is comparator -1 No	ES, n<400 -1 CI contains meaningful ES; <400 participants -1 CI spans meaningful ES, n<400 -1 CI contains meaningful	Not tested (n<10) Not tested (n<10) 0 Not tested (n<10)	Low Very low
Glycosaminoglycan Polysulphate Hyaluronic acid Platelet-rich plasma	1 RCT 1 RCT	-1 Low RoB [44] 0 High RoB [47] -1 Moderate RoB [57]	-1 One study -1 One study -1 One study	0 No 0 Military; Dose is comparator -1 No	ES, n<400 -1 CI contains meaningful ES; <400 participants -1 CI spans meaningful ES, n<400 -1 CI contains meaningful ES, n<400	Not tested (n<10) Not tested (n<10) 0 Not tested (n<10)	Low Very low Low
Glycosaminoglycan Polysulphate Hyaluronic acid Platelet-rich plasma Botox	1 RCT 1 RCT 1 RCT	-1 Low RoB [44] 0 High RoB [47] -1 Moderate RoB [57] 0	-1 One study -1 One study -1 One study -1	0 No 0 Military; Dose is comparator -1 No 0	ES, n<400 -1 CI contains meaningful ES; <400 participants -1 CI spans meaningful ES, n<400 -1 CI contains meaningful ES, n<400 -1	Not tested (n<10) Not tested (n<10) 0 Not tested (n<10) 0	Very low

Supplementary Table 2. GRADE assessment for pain outcomes

Pharmaceutical & N	utraceutical						
Transdermal							
NSAIDs	1 RCT	Moderate RoB [60]	One study	Women athletes	Values not reported,	Not tested (n<10)	Very low
(phonophoresis)		0	-1	only	n<400	0	
				-1	-1		
Corticosteroids	1 RCT	High RoB [45]	One study	Vague diagnosis,	CI spans meaningful	Not tested (n<10)	Very low
(iontophoresis,		-1	-1	sex not reported	ES, n<400	0	
phonophoresis)				-1	-1		
Surgical							
Arthroscopic							
Standard	1 RCT	High RoB [41,42]	One study	No	CI spans meaningful	Not tested (n<10)	Very low
arthroscopy		-1	-1	0	ES, n<400	0	
					-1		
Radiofrequency	1 RCT	High RoB [51]	One study	Women only,	CI exceeds meaningful	Not tested (n<10)	Very low
debridement		-1	-1	isolated PF	ES, n<400	0	
				cartilage lesions	-1		
				-1			
Surgical							
Open surgeries							
Lateral retinacular	2 RCT	Two high RoB [50,61]	No	Diagnosis specific	CI contains meaningful	Not tested (n<10)	Very low
surgery		-1	0	to lateral patellar	ES, n<400	0	
				alignment or	-1		
				hypercompression			
				-1			
Anterior tibial	1 RCT	High RoB [52]	One study	CP surgical	CI exceeds meaningful	Not tested (n<10)	Very low
tuberosity		-1	-1	candidates	ES, n<400	0	
displacement				0	-1		
Patellofemoral	2 RCT	One low RoB[40]	Effects in	Isolated PFOA	CI spans meaningful	Not tested (n<10)	Moderate
arthroplasty		One moderate RoB[43]	different	0	ES, n<400	0	
		0	directions but		-1		
			not significant				
			so results				
			similar				

6 RoB = risk of bias; RCT = randomized controlled trial; ES = effect size; PFOA = patellofemoral osteoarthritis; CI = confidence intervals

- 7 Decision guidelines for scoring: RoB: -1 for high RoB (low and moderate no reduction); Inconsistency: -1 if results differ among studies regarding significance or direction of effect; or if not enough
- 8 evidence to assess (e.g. only 1 study); Indirectness: -1 if population characteristics limit generalizability; if comparator has unknown efficacy or if pain outcome is not a validated measure; Imprecision: -1
- 9 if sample size <400, or if confident intervals are wide and either contain clinically meaningful benefit (meaningful defined as SMD 0.5 or RR 25%), or span both clinically meaningful benefit and harm.
- 10 Note if large ES (i.e. CI exceeds clinically meaningful difference), we only upgraded if study was also rated low RoB); Publication bias: only assess if at least 10 studies for every treatment comparison.
- 11

12